Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: MP0317 + Chemoimmunotherapy in First Line Advanced Biliary Tract Carcinoma
NCT07036380Phase 2Recruiting
- Sponsor
- CHU de Besançon
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of MP0317 in biliary tract carcinoma (BTC), sponsored by CHU de Besançon. Started Dec 2025; status: recruiting.
02
Drugs
MP0317
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07036380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036380.